Literature DB >> 11216959

Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk.

A von Eckardstein1, H Schulte, P Cullen, G Assmann.   

Abstract

OBJECTIVES: This prospective population study was conducted to assess the role of elevated lipoprotein(a) [Lp(a)] as a coronary risk factor.
BACKGROUND: The role of elevated Lp(a) as a risk factor for coronary heart disease is controversial. In addition, little attention has been paid to the interaction of Lp(a) with other risk factors.
METHODS: A total of 788 male participants of the Prospective Cardiovascular Münster (PROCAM) study aged 35 to 65 years were followed for 10 years. Both Lp(a) and traditional cardiovascular risk factors (e.g., age, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, triglycerides, systolic blood pressure, cigarette smoking, diabetes mellitus, angina pectoris, and family history of myocardial infarction) were evaluated in 44 men who suffered from myocardial infarction, and in 744 men who survived without major coronary events or stroke. A multiple logistic function algorithm was used to estimate global cardiovascular risk by the combined effects of traditional risk factors.
RESULTS: Overall, the risk of a coronary event in men with an Lp(a) > or =0.2 g/liter was 2.7 times that of men with lower levels (95% confidence interval [CI]: 1.4 to 5.2). This increase in risk was most prominent in men with LDL cholesterol level > or =4.1 mmol/liter (relative risk [RR]: 2.6; 95% CI: 1.2 to 5.7), with HDL cholesterol < or =0.9 mmol/liter (RR 8.3; 95% CI: 2.0 to 35.5), with hypertension (RR 3.2; 95% CI: 1.4 to 7.2), or within the two highest global risk quintiles (relative risk: 2.7; 95% CI: 1.3 to 5.7).
CONCLUSIONS: Lp(a) increases the coronary risk, especially in men with high LDL cholesterol, low HDL cholesterol, hypertension and/or high global cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11216959     DOI: 10.1016/s0735-1097(00)01126-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

1.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

2.  Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism.

Authors:  Andelko Hrzenjak; Sasa Frank; Xingde Wo; Yonggang Zhou; Theo Van Berkel; Gert M Kostner
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

Review 3.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 4.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 5.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

6.  Lipoprotein(a) and SYNTAX Score Association with Severity of Coronary Artery Atherosclerosis in North India.

Authors:  Fauzia Ashfaq; P K Goel; Nagraja Moorthy; Rishi Sethi; Mohammed Idrees Khan; Mohammed Zafar Idris
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

7.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Authors:  Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

Review 8.  The role of non-LDL:non-HDL particles in atherosclerosis.

Authors:  Jere P Segrest
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 9.  Metabolic syndrome and cardiovascular disease in South Asians.

Authors:  Danny Eapen; Girish L Kalra; Nadya Merchant; Anjali Arora; Bobby V Khan
Journal:  Vasc Health Risk Manag       Date:  2009-09-07

10.  Lipoprotein (A): Better assessor of coronary heart disease risk in south Indian population.

Authors:  D Rajasekhar; K S S Saibaba; P V L N Srinivasa Rao; S A A Latheef; G Subramanyam
Journal:  Indian J Clin Biochem       Date:  2004-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.